Houston s early-stage life science commercialization platform Evolving a Novel Approach to Life Sciences Commercialization CPRIT Conference, November 2017
Texas Medical Center City of Medicine
TMC Key Stats 58 Institutions 106,000 Employees 5,700 Researchers 10M Patient Encounters Each Year 5.9 x 8.3 x Over $1B per Year in Basic Research 1,300 Active Grants 2016 NIH Research Funding $195M $365M $427M 4,000 Active Clinical Trials $600M 3
Fannin Innovation Studio The Challenge? Over $1B in basic research funding a year but inadequate commercialization. Over 8,000 early-career scientists and engineers but lack critical mass of entrepreneurs. What We Do Build successful life sciences startups Help catalyze life sciences ecosystem. 4
Our Approach We bridge the gap between academic research and clinical proof of concept. How? We in-license and internally develop assets/technologies. We drive early R&D through clinical proof of concept. We partner or spin-out an asset when ready. 5
The Studio In a Nutshell An integrated approach to life sciences and human capital development Experienced Management Team Early Project Funding Internship & Fellowship Programs Non-Dilutive and Investor Capital 6 Infrastructure & Resources
How The Studio Works MANAGEMENT Fannin Management Team Transitional Management Team Stand-alone Management Team SCIENTIFIC LEADERSHIP Founding Scientists Founding Scientists, External Experts ACTIVITIES AND GOALS License Assets or Technology from Institution De-Risk Asset Establish Clinical Proof of Concept PRODUCT OR PARTNERSHIP CAPITAL Fannin and Grant Funding Grant or Angel Funding Strategic or Venture Funding 7
Funding Support and Recognition 20 SBIR/STTR Grants Awarded $10.3M Total SBIR/STTR Funding Awarded Funding $10.6M Additional Non-SBIR/STTR Grant Funding $30M Total Investor Dollars Raised Across Technologies Tibbetts Award 2016 2016, 2017 National Growth Accelerator Award Fannin Model Discussed in Press: Top of Texas 2016 - Xconomy Building An Entrepreneurial Health Sciences Ecosystem From The Ground Up - Life Science Leader Building the Next Generation of CEOs: Houston s Fannin Names Fellows - Xconomy Startup studio overcoming an entrepreneur shortage Houston Chronicle 12
Active Programs - 35 Technologies Licensed Since Inception - Eleven Institutions Across Texas - Sixteen Active Programs - Nine Oncology Programs - Two CPRIT funded 8
Case Study: Pulmotect, Inc. Completed Phase 1 after ~$1M in investor capital + $18M+ institutional/grant funds 2013-2015 ü $230K Phase I SBIR Grant ü $1M Phase 2 SBIR Grant ü $2M Phase 2 SBIR Grant ü $500K private placement ü IND enabling GLP Tox Studies ü FDA IND and Phase I Clinical Study 2016-2017 ü $3M Phase IIB SBIR Grant ü $2.1M Series A Investment ü Second FDA IND (antiviral division) ü Completed 2 Phase I clinical trials in healthy patients ü Initiated Phase IB clinical trial in cancer patients ü Assembled world-class Scientific Advisory Board ü Expanded Management Team ü Filed for orphan drug status 4 Years from lead molecule to completed Phase 1 Clinical Trial 2011-2012 ü $1.5M Phase II SBIR Grant ü $600K third party angel investment ü $7.1M CPRIT grant (tranched through Phase 2) 2009-2010 ü $1M Texas Emerging Technology Fund Award ü Preclinical proof of concept studies ü Lead molecule (PUL-042) identified ü $200K Phase I SBIR Grant 2007-2008 ü Company founded; MD Anderson / TX A&M technology ü$2.3m UO1 Grant Award 9
Core Fannin Team and Portfolio Leadership 10
Our Inventors and Academic Collaborators 11
Our Internship Program Leverages >8,000 early-career scientists and engineers with limited entrepreneurship opportunities/experience Provides experiential learning through hands-on development with life sciences startups 13
Contact Us Atul Varadhachary Managing Partner atul@fannininnovation.com www.fannininnovation.com @FanninStudio Fannin Innovation 17